AMRX Latest Headlines

Amneal Exceeds 2025 Guidance and Eyes More Growth for 2026 as Portfolio Strengthens

Market Chameleon (Fri, 27-Feb 9:21 AM)

Amneal Pharmaceuticals: Portfolio Shift to High-Margin Brands and Biosimilars Supports Buy Rating and Upside to $17 Target

at www.tipranks.com (Fri, 27-Feb 3:35 PM)

Amneal outlines 2026 guidance with 12% to 24% EPS growth target, signals acceleration in affordable medicines

at seekingalpha.com (Fri, 27-Feb 10:18 AM)

Amneal Posts Strong Q4 Results and Raises 2026 Outlook

at www.tipranks.com (Fri, 27-Feb 8:03 AM)

Options Volatility and Implied Earnings Moves Today, February 27, 2026

at www.tipranks.com (Fri, 27-Feb 7:05 AM)

Amneal Pharmaceuticals Non-GAAP EPS of $0.21 beats by $0.03, revenue of $814M beats by $6.68M

at seekingalpha.com (Fri, 27-Feb 6:09 AM)

Here are the major earnings before the open Friday

at seekingalpha.com (Thu, 26-Feb 6:00 PM)

Amneal Pharmaceuticals Q4 2025 Earnings Preview

at seekingalpha.com (Thu, 26-Feb 10:41 AM)

AMRX to Join S&P SmallCap 600 Amid Index Shuffle: What the Move Means for Investors

Market Chameleon (Wed, 28-Jan 9:29 AM)